NTRA
Natera Inc
$268.53
0.86 (0.32%) Today
2.92 (1.08%) After-hours
— up— down
Market Cap
$38.88B+60.7%
Revenue (TTM)
$2.53B+36.6%
Net Income (TTM)
$-234,580,038
$-234,580,038EPS (TTM)
-1.64
-1.64Shares Out
143.22M
143.22MOpen
$271.45
$271.45Previous Close
$272.31
$272.31Day Range
$265.39 – $275.24
$265.39 – $275.2452-Week Range
$131.81 – $275.24
$131.81 – $275.24Beta
1.51
1.51Volume
1.34M
1.34MAvg Volume
1.46M
1.46MAnalyst Rating
Buy
BuyExchange
NASDAQ NMS - GLOBAL MARKET
NASDAQ NMS - GLOBAL MARKETAbout NTRA
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women's health, cancer, and organ health. Natera's proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas.
Related
News
N/AN/A
N/AN/A
Guggenheim Maintains Buy on Natera, Raises Price Target to $290
Benzinga · 1d ago
Natera Partners With Aveta On Late-Stage Head And Neck Cancer Trial
Benzinga · 1d ago
Natera: All-Time Share Price High A Potential Caveat For Investors, Despite Promise
SeekingAlpha · 4d ago
CORRECTION: Bernstein Reinstates Outperform on Natera, Announces $310 Price Target
Benzinga · 4d ago
Natera Partners With Eledon Pharmaceuticals To Incorporate Its Prospera Kidney Transplant Assessment Test Into Eledon’s Planned Phase 3 Clinical Trial Of Tegoprubart, An Investigational Therapy Designed To Prevent Organ Rejection In Kidney Transplantation
Benzinga · 5d ago